TY - JOUR T1 - Clinical exome sequencing for stroke evaluation uncovers a high frequency of Mendelian disorders: a retrospective analysis JF - medRxiv DO - 10.1101/2022.06.10.22276114 SP - 2022.06.10.22276114 AU - Runjun D. Kumar AU - Linyan Meng AU - Pengfei Liu AU - Christina Y. Miyake AU - Kim C. Worley AU - Weimin Bi AU - Seema R. Lalani Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/14/2022.06.10.22276114.abstract N2 - Background Stroke causes significant disability and is a common cause of death worldwide. Previous studies have estimated that 1-5% of stroke is attributable to monogenic etiologies. We set out to assess the utility of clinical exome sequencing (ES) in the evaluation of stroke.Methods We retrospectively analyzed 124 individuals who received ES at the Baylor Genetics reference lab between 2012 and 2021 who had stroke as a major part of their reported phenotype.Results Ages ranged from 10 days to 69 years. 8.9% of the cohort received a diagnosis, including 25% of infants less than 1 year old; an additional 10.5% of the cohort received a probable diagnosis. We identified several syndromes that predispose to stroke such as COL4A1-related brain small vessel disease, CBS-related homocystinuria, POLG-related disorders, TTC19-related mitochondrial disease, and RNASEH2A associated Aicardi-Goutieres syndrome. We also observed pathogenic variants in NSD1, PKHD1, HRAS and ATP13A2, which are genes rarely associated with stroke.Conclusions Although stroke is a complex phenotype with varying pathologies and risk factors, these results show that use of exome sequencing can be highly relevant in stroke, especially for those presenting <1 year of age.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by 3UM1HG006348-10S2 to SRL, 1R03OD030597-01 to KW and SRL and K23HL136932 to CYM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The internal review board (IRB) of Baylor College of Medicine gave ethical approval of this work (IRB protocol H-41191). IRB approval included waiver of consent for publication of individual-level data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data described in this study are provided within the article and supplementary materials. Additional de-identified clinical data is available upon request to the corresponding author. ER -